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Current guidelines (1) and expert opinion (2) do not
recommend routine electrophysiologic (EP) study in pa-
tients with asymptomatic Wolff-Parkinson-White (WPW)
syndrome. Patients who engage in “high-risk” occupations
or those patients in whom a pre-excitation pattern precludes
them from following their chosen career may be exceptions.
In this issue of the Journal, Pappone et al. (3) report the
results of a five-year follow-up of a cohort of 212 patients
with asymptomatic WPW. During the follow-up period,
one patient died from ventricular fibrillation (VF), and two
patients had a cardiac arrest due to VF from which they
were successfully resuscitated. These findings contrast to
previous studies (4–14) that have found asymptomatic
WPW to be associated with a good prognosis (Table 1). In
light of the findings of Pappone et al. (3), it is important to
ask whether we should re-address the issue of routine EP
testing for asymptomatic WPW.
See page 239
The study of Pappone et al. (3) is commendable for
recruiting patients that were genuinely asymptomatic at the
time of diagnosis. Evidence of the WPW pattern was found
incidentally in all patients either at a routine medical
examination or on a screening electrocardiogram before
admission to competitive sport or a high-risk occupation.
All patients underwent a baseline EP study and a repeat EP
study after five years of follow-up or earlier if symptoms
developed. Unfortunately, a large number of patients (50
patients) are excluded from the final analysis.
Over the period of the study, a number of patients
became symptomatic (33 of 162 patients, 20.4%). These
patients were, on average, younger than those who did not
become symptomatic (20.1  8.6 years vs. 37.1  13.4
years, p  0.0001). At the initial EP study, 29 of these 33
(88%) patients had inducible atrioventricular re-entrant
tachycardia (AVRT). Atrioventricular re-entrant tachycar-
dia degenerated into pre-excited atrial fibrillation (AF) in 11
of these 29 patients, with a mean shortest pre-excited RR
(SPRR) interval of 223 ms. After the onset of symptoms,
spontaneous arrhythmias were documented in all 33 pa-
tients, in the form of supraventricular tachycardia in 25
patients and AF in 8 patients. All eight patients with
spontaneous AF had both inducible AVRT and pre-excited
AF during the initial EP study. It is interesting to note that
only 1 of the 30 patients with inducible AVRT at the initial
study remained asymptomatic, and only 4 of the 115
noninducible patients developed symptoms during follow-
up. The occurrence of nonsustained AF (17 patients) after
rapid atrial pacing at the initial EP study was not a good
predictor of future symptoms. Importantly, the three pa-
tients who had a VF arrest had both AVRT and AF at the
time of the initial EP study and documented spontaneous
AF during follow-up. All had been offered ablation after the
recognition of spontaneous AF but had declined.
In addition to assessing the inducibility of tachycardia,
the initial EP study highlighted other factors that suggest a
patient may subsequently develop symptoms. The presence
of multiple accessory pathways (APs) (15/33 vs. 1/129, p 
0.0001) suggests that the patient is more likely to become
symptomatic. Multiple APs are also known to increase the
risk of VF in WPW patients (15) and were present in all
three patients who subsequently had VF. A shorter ante-
grade effective refractory period of the AP was also associ-
ated with symptoms during follow-up, although this was a
much weaker predictor than multiple pathways or inducible
AVRT.
The authors conclude that, in asymptomatic WPW, a
negative EP study identifies subjects at low risk of future
arrhythmic events (AVRT, AF, and VF), and that EP
testing is a valuable tool in predicting future arrhythmias. A
positive EP study (inducible sustained or nonsustained
AVRT and/or AF) has positive and negative predictive
values of 87.9% and 86.0% for the prediction of future
arrhythmic events. It is noteworthy that AF was induced in
only 17% of patients studied, which is considerably less than
in previous series (7).
Do these findings provide a compelling argument for
routine EP testing of all asymptomatic WPW patients? The
principal argument for EP testing of asymptomatic WPW
patients is to identify patients at risk of subsequent VF,
rather than to identify those that may become symptomatic
later in life, as occurrence of any other arrhythmia by and
large provides abundant opportunity to direct curative treat-
ment at those who have declared themselves. Although all
the patients were asymptomatic at the time of diagnosis, the
three patients who subsequently had VF in this study all
developed symptomatic AF before this event. If one had
pursued a strategy of selecting patients for EP testing at the
development of symptoms, it is likely that no patient would
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have had VF, only 33 patients would have been ablated, and
129 patients would have been spared an invasive study.
Sudden cardiac death can be the first presenting symptom
of WPW in some patients, which has been the basis of the
argument for EP testing of asymptomatic patients. In the
three largest series of WPW patients with VF published,
VF was the initial presenting symptom in 3/25 patients
(16), 6/23 patients (17), and 8/15 patients (18). It is,
however, a rare initial presentation in patients over 30 years
of age (16,19). The true incidence of VF in asymptomatic
WPW is, of course, much lower than suggested by these
studies, which all suffer from selection bias, as they were
based in major cardiac centers. They, nonetheless, highlight
the potential for VF to be the presenting arrhythmia in
WPW.
Assessment of the future VF risk in an asymptomatic
patient with WPW is not easy. Noninvasive markers of
lower risk such as intermittent loss of pre-excitation (20),
sudden loss of AP conduction on exercise stress testing
(21,22), and loss of AP conduction after treatment with
antiarrhythmic drugs (23) are limited by inadequate sensi-
tivity or specificity and the low incidence of future adverse
events. Invasive EP assessment also has drawbacks, as no
single factor has both a high sensitivity and specificity for
identifying at-risk individuals. For instance, an SPRR of
250 ms during sustained induced AF is a very sensitive
(16), but not specific, marker of the risk of VF in WPW
patients, as approximately one-third of patients (7,9) with
asymptomatic WPW will have an SPRR of 250 ms
during induced AF. The presence of inducible AVRT,
although less directly linked to the mechanism of VF than
the short pre-excited RR intervals in AF, is a more specific
marker of future symptoms and VF risk. The generally
accepted mechanism for sudden cardiac death in WPW is
the onset of AVRT that degenerates into AF then into VF
(16,17). The likelihood of an asymptomatic WPW patient
having sustained AVRT in the future is much greater if the
AP can conduct retrogradely (7) or sustain AVRT (6) at EP
study. In the current study (3), inducible AVRT that
degenerated into AF occurred in all three patients who
subsequently had VF.
Short pre-excited RR intervals in AF (250 ms) have
traditionally received more attention as a risk factor for VF
than inducible AVRT. This is reasonable because it is
almost a universal finding in patients with VF. Studies of
WPW patients with VF have focused primarily on compar-
ing VF patients to symptomatic WPW patients without
VF. Inducible AVRT was present at EP study in most
patients in both groups and, therefore, was not identified as
a strong independent marker of future risk. However, the
situation is different in asymptomatic WPW where the
presence of inducible AVRT, especially when it triggers AF,
represents a more specific marker for future symptoms and
VF risk.
The basic premise of investigating and treating an asymp-
tomatic patient is, first, to do no harm. In the current era of
radiofrequency (RF) ablation, a combined diagnostic and
therapeutic procedure has become standard clinical practice.
If routine EP testing of all asymptomatic WPW patients is
considered, we must recognize that many patients will
proceed immediately to RF ablation. Approximately one-
third of patients will have an SPRR of 250 ms during
induced AF, and, in others, there will be a strong tempta-
tion to ablate when catheters are in place. This greatly
increases the risk to the patient. Most complications of a
diagnostic EP study are minor and non-life-threatening.
However, RF ablation is associated with serious complica-
tions such as myocardial infarction, stroke, cardiac tampon-
ade, requirement for urgent cardiac surgery, and death. The
rates of significant complications during RF ablation of APs
reported in the Multicentre European Radiofrequency Sur-
vey (MERFS) (24), the 1993 North American Society of
Table 1. The Natural History of Asymptomatic WPW
Authors
Number of
Patients
EP
Study
Induced Arrhythmias
SCD
Follow-up
(yrs)AVRT AF SPRR
Electrophysiology-Based Studies
Klein (4) 29 yes 17% 31% 0 4.5*
Satoh (5) 34 yes 18% 3% 0 1.3
Beckman (6) 15 yes 20% 13% 0 7.5
Leitch (7) 75 yes 16% 31% 0 4.3*
Fukatani (8) 64 yes n/a n/a 0 6.6
Brembilla-Perrot (9) 40 yes 7.5% 12.5% 0 1.8
Population-Based Studies
Berkman (10) 128 no 13.3% 3 symptoms 0 18
Soria (11) 78 no n/a 2 5.7
Munger (12) 53 no 21% 3 symptoms 0 10.1
Goudevenos (13) 77 no 4% 3 symptoms 0 4.6
Fitzsimmons (14) 187 no 15% 3 symptoms 0 21.8
*There is some overlap in the patients reported in these two studies.
AF SPRR  atrial fibrillation with a shortest pre-excited RR interval of 250 ms; AVRT  atrioventricular re-entrant
tachycardia; EP  electrophysiologic; n/a  not quoted in paper; SCD  sudden cardiac death; WPW  Wolff-Parkinson-
White syndrome.
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Pacing and Electrophysiology (NASPE) survey of catheter
ablation (25), and from the Atakr study (26) are summa-
rized in Table 2. An overall risk of around 2% is especially
significant to an asymptomatic, young patient. We should
also keep in mind that the published results are likely to
represent the better end of the spectrum, as they are based
on voluntary registries from experienced high-volume cen-
ters.
Should the current guidelines be changed? It is difficult to
make a strong recommendation for a strategy that, in the
final analysis, will arguably result in comparable morbidity
and mortality to the problem addressed. The key is a clear
understanding by the patient of the relative merits of each
strategy. The well-informed patient needs to choose be-
tween a very small risk over a long period of time and a
one-time risk over a short span (i.e., ablation). Certain
patients such as athletes and those in “higher-risk” occupa-
tions will generally choose ablation. Others, especially older
patients (30 years), may prefer the small risk of a conser-
vative strategy. In the continuing absence of symptoms, the
risk of future VF is low. The physician should also remem-
ber that the risks and success rates of ablation vary according
to pathway location. Ablation of pathways in the septal area
carries a significant risk of heart block, and ablation of
left-sided pathways is associated with the risks of trans-
septal puncture or the retrograde aortic approach. If an EP
study is performed for risk stratification, the combination of
inducible AVRT and a shortest pre-excited RR interval in
AF of250 ms provide the most compelling indications for
ablation.
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